|
Paul M. Herron, M.B.A., Vice President, Business Development & Chief Financial Officer
Mr. Herron has over thirty years of corporate finance experience, including twenty years in the biopharmaceutical industry. Prior to joining Altor in March 2007, Mr. Herron was Chief Financial Officer and acting CEO for Osprey Pharmaceutical Company in Jacksonville, Florida. Osprey was a privately funded startup company licensing University of Florida technology for the development of a nicotinic receptor agonist showing activity in memory and cognition. Mr. Herron successfully completed the sale of the company’s assets to Athenagen, Inc. (now CoMentis, Inc.) in 2006. Previously, from 2000 to 2003, Mr. Herron served as CFO for Copharos, Inc., a venture-funded startup licensing technology from Mayo Clinic, and from 1997 to 1999 as CFO of SunPharm Corporation, a publicly held biopharmaceutical company which was sold to GelTex Pharmaceuticals. From 1994 to 1997 he was Director of Finance and Investor Relations for Immunomedics, Inc., a public company active in the development of monoclonal antibodies. From 1989 to 1994 Mr. Herron served as Finance Manager for two operating businesses of the DuPont Merck Pharmaceutical Company-- nuclear medicine and generic pharmaceuticals. Prior to joining DuPont Merck he served in a variety of financial analysis, tax and accounting assignments with E.I. du Pont de Nemours & Company, beginning in 1976. Mr. Herron earned his MBA from Duke University and has a BA in economics from Trinity College, Hartford, Connecticut. He is a past chairman of the Business Solutions Advisory Board for the Biotechnology Industry Organization in Washington, DC. | 